Aton Prepares European Rollout of Pims, Its Cancer Treatment Response Analysis Platform
Aton Group introduces its subsidiary Pims Technology and its molecular analysis platform designed to early identify patients responding to cancer treatments. The group has begun discussions to implement its technology in European cancer centers by 2026.
A Technology to Assess Patient Therapeutic Response
Pims Technology develops the proprietary Pims technology (Physiological Inter-Molecular Modulation Spectroscopy), resulting from over ten years of research and protected by several patents. This technology analyzes the dynamic interactions between proteins and macromolecules in a patient's biological sample, generating a molecular fingerprint that assesses the biological response to a treatment, either before or during the treatment process. The Pims Q8 platform combines advanced spectroscopy and proprietary analysis software in a hospital-compatible environment. It aims to address a major challenge in personalized medicine: the early identification of responders and non-responders.
Planned Deployment in Leading European Centers
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Pims Technology is currently engaged in advanced discussions aimed at implementing its platform within internationally renowned oncology reference centers. This deployment phase represents the first milestone in the company's international expansion strategy, with a planned implementation at the heart of European oncology hubs in 2026. According to Aton, this step constitutes a major clinical validation of the technology. The group notes that two programs are underway in this context, without detailing their specific nature.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 2025
Key reported figures
Revenue: 0.7M€
EBITDA: -0,1M€
Net income: -1,0M€
3.1M€
Guidance from the release
En 2025, nous avons tenu nos engagements : structure de coûts assainie, filiales en ordre de marche, premiers jalons commerciaux posés.
Le Groupe Aton a réalisé une amélioration relative de la performance opérationnelle.
Risks mentioned
Environnement de financement toujours sélectif pour les sociétés de biotechnologies.
Risque lié à la montée en volumes de production d'anticorps à récepteurs Fc humain.
Opportunities identified
Signature de nouveaux partenariats industriels stratégiques.
Obtention d'un financement de 500 K€ de Bpifrance.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
